234 related articles for article (PubMed ID: 15691312)
21. [Eradication of Helicobacter pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2002].
Buzás GM; Józan J
Orv Hetil; 2004 Oct; 145(40):2035-41. PubMed ID: 15559530
[TBL] [Abstract][Full Text] [Related]
22. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies.
Fischbach LA; van Zanten S; Dickason J
Aliment Pharmacol Ther; 2004 Nov; 20(10):1071-82. PubMed ID: 15569109
[TBL] [Abstract][Full Text] [Related]
23. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea.
Kim BG; Lee DH; Ye BD; Lee KH; Kim BW; Kim SG; Kim SW; Kim SK; Kim JJ; Kim HY; Park JJ; Park CY; Baik GH; Lee YC; Lee JH; Lee JH; Chun HJ; Hahm KB; Hong SJ; Lee SW; Jung HC
Helicobacter; 2007 Feb; 12(1):31-5. PubMed ID: 17241298
[TBL] [Abstract][Full Text] [Related]
24. Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen.
Nagahara A; Miwa H; Kawabe M; Kurosawa A; Asaoka D; Hojo M; Iijima K; Terai T; Ohkusa T; Miyazaki A; Sato N
J Gastroenterol; 2004 Nov; 39(11):1051-5. PubMed ID: 15580397
[TBL] [Abstract][Full Text] [Related]
25. Eradication therapies for Helicobacter pylori.
Borody TJ; Shortis NP; Reyes E
J Gastroenterol; 1998; 33 Suppl 10():53-6. PubMed ID: 9840019
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area.
Matsuhisa T; Kawai T; Masaoka T; Suzuki H; Ito M; Kawamura Y; Tokunaga K; Suzuki M; Mine T; Takahashi S; Sakaki N
Helicobacter; 2006 Jun; 11(3):152-8. PubMed ID: 16684262
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of the effectiveness of tri- and quadricomponent eradication therapy in patients with peptic ulcer].
Butorov IV; Osoianu IuP; Butorov SI; Maksimov VV
Klin Med (Mosk); 2005; 83(12):50-3. PubMed ID: 16502725
[TBL] [Abstract][Full Text] [Related]
28. 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure.
Gisbert JP; Fuentes J; Carpio D; Tito L; Guardiola J; Tomas A; Olivares D; Calvet X
Aliment Pharmacol Ther; 2005 May; 21(10):1249-53. PubMed ID: 15882246
[TBL] [Abstract][Full Text] [Related]
29. High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis.
Severi C; Abdullahi M; Tari R; Vannella L; Marcheggiano A; Capoccia D; Leonetti F; Osborn J; Annibale B
Dig Liver Dis; 2009 Aug; 41(8):555-8. PubMed ID: 19179127
[TBL] [Abstract][Full Text] [Related]
30. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
[TBL] [Abstract][Full Text] [Related]
31. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
[TBL] [Abstract][Full Text] [Related]
32. 4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection.
de Boer WA; van Etten RJ; Schade RW; Ouwehand ME; Schneeberger PM; Tytgat GN
Am J Gastroenterol; 1996 Sep; 91(9):1778-82. PubMed ID: 8792697
[TBL] [Abstract][Full Text] [Related]
33. Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Murakami K; Okimoto T; Kodama M; Sato R; Miyajima H; Ono M; Inoue K; Watanabe K; Otsu S; Fujioka T
Helicobacter; 2006 Oct; 11(5):436-40. PubMed ID: 16961805
[TBL] [Abstract][Full Text] [Related]
34. [Methods to optimize the management of Helicobacter pylori infection. The comparative efficacy of the triple and quadruple therapy used as a first line therapy].
Grigor'ev PIa; Iakovenko AV; Iakovenko EP; Vasil'ev IV; Komleva IuV; Oprishchenko IV; Aldiiarova MA
Eksp Klin Gastroenterol; 2004; (5):31-8, 148. PubMed ID: 15770858
[TBL] [Abstract][Full Text] [Related]
35. Quadruple therapy with lactoferrin for Helicobacter pylori eradication: a randomised, multicentre study.
Zullo A; De Francesco V; Scaccianoce G; Hassan C; Panarese A; Piglionica D; Panella C; Morini S; Ierardi E
Dig Liver Dis; 2005 Jul; 37(7):496-500. PubMed ID: 15975536
[TBL] [Abstract][Full Text] [Related]
36. Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori.
Graham DY; Opekun AR; Belson G; El-Zimaity HM; Carlson MR
Aliment Pharmacol Ther; 2005 Jan; 21(2):165-8. PubMed ID: 15679766
[TBL] [Abstract][Full Text] [Related]
37. Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
Güliter S; Keleş H; Ozkurt ZN; Cengiz DU; Kolukisa E
Turk J Gastroenterol; 2005 Mar; 16(1):29-33. PubMed ID: 16252185
[TBL] [Abstract][Full Text] [Related]
38. Levofloxacin- vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure.
Gisbert JP; Gisbert JL; Marcos S; Moreno-Otero R; Pajares JM
Helicobacter; 2007 Feb; 12(1):68-73. PubMed ID: 17241304
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of triple and quadruple Helicobacter pylori eradication therapies in Iranian children: a randomized clinical trial.
Bahremand S; Nematollahi LR; Fourutan H; Tirgari F; Nouripour S; Mir E; Aghakhani S
Eur J Gastroenterol Hepatol; 2006 May; 18(5):511-4. PubMed ID: 16607146
[TBL] [Abstract][Full Text] [Related]
40. Helicobacter pylori eradication in renal recipient: triple or quadruple therapy?
Hosseini SM; Sharifipoor F; Nazemian F; Ghanei H; Zivarifar HR; Fakharian T
Acta Med Iran; 2014; 52(4):271-4. PubMed ID: 24901856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
